In conclusion, the CD11b+ subpopulation in AML and MDS can remarkably respond IFN-γ and employ adaptive resistance mechanisms comprising STAT3 and PD-1 pathways. This evidence concerns the gene PDCD1 and acute myeloid leukemia.